PL3519420T3 - Cykliczne związki dinukleotydowe - Google Patents
Cykliczne związki dinukleotydoweInfo
- Publication number
- PL3519420T3 PL3519420T3 PL17772731T PL17772731T PL3519420T3 PL 3519420 T3 PL3519420 T3 PL 3519420T3 PL 17772731 T PL17772731 T PL 17772731T PL 17772731 T PL17772731 T PL 17772731T PL 3519420 T3 PL3519420 T3 PL 3519420T3
- Authority
- PL
- Poland
- Prior art keywords
- cyclic dinucleotide
- dinucleotide compounds
- compounds
- cyclic
- dinucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16191919 | 2016-09-30 | ||
EP17772731.0A EP3519420B1 (en) | 2016-09-30 | 2017-09-28 | Cyclic dinucleotide compounds |
PCT/EP2017/074608 WO2018060323A1 (en) | 2016-09-30 | 2017-09-28 | Cyclic dinucleotide compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
PL3519420T4 PL3519420T4 (pl) | 2021-08-16 |
PL3519420T3 true PL3519420T3 (pl) | 2021-08-16 |
Family
ID=57103851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17772731T PL3519420T3 (pl) | 2016-09-30 | 2017-09-28 | Cykliczne związki dinukleotydowe |
Country Status (33)
Country | Link |
---|---|
US (1) | US10537590B2 (pl) |
EP (1) | EP3519420B1 (pl) |
JP (1) | JP6509445B2 (pl) |
KR (2) | KR20220084206A (pl) |
CN (1) | CN109843903B (pl) |
AR (1) | AR109777A1 (pl) |
AU (1) | AU2017333933B2 (pl) |
BR (1) | BR112019006512A2 (pl) |
CA (1) | CA3038860C (pl) |
CL (1) | CL2019000775A1 (pl) |
CO (1) | CO2019003178A2 (pl) |
CY (1) | CY1124638T1 (pl) |
DK (1) | DK3519420T3 (pl) |
EA (1) | EA037030B1 (pl) |
ES (1) | ES2848724T3 (pl) |
HR (1) | HRP20210027T1 (pl) |
HU (1) | HUE053819T2 (pl) |
IL (1) | IL265642B (pl) |
JO (1) | JOP20190066B1 (pl) |
LT (1) | LT3519420T (pl) |
MA (1) | MA46325B1 (pl) |
MX (1) | MX2019003586A (pl) |
NZ (1) | NZ750906A (pl) |
PE (1) | PE20191503A1 (pl) |
PH (1) | PH12019500706A1 (pl) |
PL (1) | PL3519420T3 (pl) |
PT (1) | PT3519420T (pl) |
RS (1) | RS61423B1 (pl) |
SA (1) | SA519401435B1 (pl) |
SI (1) | SI3519420T1 (pl) |
TW (1) | TWI774697B (pl) |
UA (1) | UA124347C2 (pl) |
WO (1) | WO2018060323A1 (pl) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3429596T (pt) | 2016-03-18 | 2022-11-25 | Immune Sensor Llc | Compostos de dinucleotídeos cíclicos e métodos de utilização |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
CR20190181A (es) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
AU2018254577B2 (en) | 2017-04-21 | 2024-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
US11773132B2 (en) | 2017-08-30 | 2023-10-03 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
BR112020009126A2 (pt) | 2017-11-10 | 2020-10-20 | Takeda Pharmaceutical Company Limited | compostos do modulador sting e métodos de fabricação e uso |
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
CN111989338A (zh) * | 2018-03-27 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 修饰的环二核苷酸化合物 |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
WO2019227007A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
WO2020036199A1 (en) | 2018-08-16 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Salts of compounds and crystals thereof |
IL281247B1 (en) | 2018-09-06 | 2024-09-01 | Daiichi Sankyo Co Ltd | New derivatives of cyclic dinucleotides and their antibody-drug conjugates |
CA3111784A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Methods and compositions for the treatment of disease with immune stimulatory conjugates |
CA3113425A1 (en) | 2018-09-21 | 2020-03-26 | Shanghai De Novo Pharmatech Co., Ltd. | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application |
WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
EP3873903B1 (en) | 2018-10-31 | 2024-01-24 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
KR20210137518A (ko) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
CN114127082A (zh) | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
WO2020229982A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
MX2022003658A (es) | 2019-09-30 | 2022-04-25 | Gilead Sciences Inc | Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb. |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
BR112022015283A2 (pt) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco incluindo derivados de dinucleotídeos cíclicos |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
AU2021276332A1 (en) | 2020-05-19 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
PE20230779A1 (es) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico |
EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
CA3191395A1 (en) | 2020-09-02 | 2022-03-10 | Daiichi Sankyo Company, Limited | Novel endo-.beta.-n-acetylglucosaminidase |
WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
KR20230107586A (ko) | 2020-10-20 | 2023-07-17 | 타이리간드 바이오사이언스 (상하이) 리미티드 | 다기능성 사이클릭 디뉴클레오티드 및 이의 용도 |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Fc分子之製造方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009418A2 (en) * | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
WO2005087238A2 (en) * | 2004-03-15 | 2005-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2012004367A1 (en) | 2010-07-09 | 2012-01-12 | N.V. Organon | Agonistic antibody to cd27 |
WO2014093936A1 (en) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
CA2895175C (en) | 2012-12-19 | 2021-06-01 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | I型インターフェロンの環状ジヌクレオチド誘導法 |
RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
MX2016015928A (es) | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
TN2017000375A1 (en) | 2015-03-10 | 2019-01-16 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
US10738074B2 (en) | 2015-08-13 | 2020-08-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as STING agonists |
-
2017
- 2017-09-27 US US15/716,720 patent/US10537590B2/en active Active
- 2017-09-28 BR BR112019006512A patent/BR112019006512A2/pt active IP Right Grant
- 2017-09-28 RS RS20210104A patent/RS61423B1/sr unknown
- 2017-09-28 MA MA46325A patent/MA46325B1/fr unknown
- 2017-09-28 EA EA201990785A patent/EA037030B1/ru not_active IP Right Cessation
- 2017-09-28 PE PE2019000722A patent/PE20191503A1/es unknown
- 2017-09-28 NZ NZ750906A patent/NZ750906A/en unknown
- 2017-09-28 KR KR1020227019917A patent/KR20220084206A/ko active Application Filing
- 2017-09-28 PL PL17772731T patent/PL3519420T3/pl unknown
- 2017-09-28 ES ES17772731T patent/ES2848724T3/es active Active
- 2017-09-28 JO JOP/2019/0066A patent/JOP20190066B1/ar active
- 2017-09-28 EP EP17772731.0A patent/EP3519420B1/en active Active
- 2017-09-28 UA UAA201904428A patent/UA124347C2/uk unknown
- 2017-09-28 LT LTEP17772731.0T patent/LT3519420T/lt unknown
- 2017-09-28 WO PCT/EP2017/074608 patent/WO2018060323A1/en active Application Filing
- 2017-09-28 KR KR1020197012683A patent/KR102536447B1/ko active IP Right Grant
- 2017-09-28 CN CN201780064246.7A patent/CN109843903B/zh active Active
- 2017-09-28 PT PT177727310T patent/PT3519420T/pt unknown
- 2017-09-28 JP JP2018530574A patent/JP6509445B2/ja active Active
- 2017-09-28 SI SI201730631T patent/SI3519420T1/sl unknown
- 2017-09-28 DK DK17772731.0T patent/DK3519420T3/da active
- 2017-09-28 AU AU2017333933A patent/AU2017333933B2/en active Active
- 2017-09-28 HU HUE17772731A patent/HUE053819T2/hu unknown
- 2017-09-28 MX MX2019003586A patent/MX2019003586A/es unknown
- 2017-09-28 CA CA3038860A patent/CA3038860C/en active Active
- 2017-09-29 TW TW106133691A patent/TWI774697B/zh active
- 2017-09-29 AR ARP170102737A patent/AR109777A1/es unknown
-
2019
- 2019-03-25 CL CL2019000775A patent/CL2019000775A1/es unknown
- 2019-03-26 IL IL265642A patent/IL265642B/en unknown
- 2019-03-27 SA SA519401435A patent/SA519401435B1/ar unknown
- 2019-03-29 CO CONC2019/0003178A patent/CO2019003178A2/es unknown
- 2019-04-01 PH PH12019500706A patent/PH12019500706A1/en unknown
-
2021
- 2021-01-07 HR HRP20210027TT patent/HRP20210027T1/hr unknown
- 2021-02-08 CY CY20211100105T patent/CY1124638T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265642B (en) | Cyclic dinucleotide compounds | |
IL268799A (en) | Modified cyclic dinucleotide compounds | |
GB201616511D0 (en) | Novel compounds | |
GB201614134D0 (en) | Novel compounds | |
GB201616627D0 (en) | Novel compounds | |
GB201604647D0 (en) | Novel compounds | |
GB201610147D0 (en) | Novel compounds | |
GB201604638D0 (en) | Novel compounds | |
GB201602854D0 (en) | Novel compounds | |
GB201603779D0 (en) | Novel compounds | |
GB201602934D0 (en) | Compounds | |
GB201604020D0 (en) | Compounds | |
GB201604027D0 (en) | Compounds | |
GB201613163D0 (en) | Novel compounds | |
GB201608777D0 (en) | Compounds | |
GB201604022D0 (en) | Compounds | |
GB201604030D0 (en) | Compounds | |
GB201618346D0 (en) | Novel compounds | |
GB201619514D0 (en) | Novel compounds | |
GB201604029D0 (en) | Compounds | |
GB201601301D0 (en) | Novel compounds | |
GB201615191D0 (en) | Novel compounds | |
GB201604031D0 (en) | Compounds | |
GB201616907D0 (en) | Novel Compounds | |
GB201616348D0 (en) | Novel compounds |